Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GENZYME CLINDAMYCIN PHOSPHATE ANDA APPROVED

Executive Summary

GENZYME CLINDAMYCIN PHOSPHATE ANDA APPROVED, the Boston, Mass.-based company announced in a Nov. 4 press release. The hospital infection antibiotic will be the first product to be manufactured at Genzyme's new pharmaceutical production facility in Haverhill, England. Genzyme plans to manufacture and distribute the antibiotic immediately. Previously, Genzyme has produced nicofuranose in bulk for one pharmaceutical manufacturer. FDA began approving ANDAs for generic clindamycin in 1987. "The U.S. market for bulk clindamycin is $ 35-40 million annually," the press release states. "Finished product sales are approximately $ 200 million." Upjohn's Cleocin brand, however, has been declining in sales sharply in the past year, probably lowering the full market estimate. The biotech firm has predicted that the new manufacturing facility would generate sales exceeding $ 11 mil. in 1988, with exports accounting for 85% of the revenue ("The Pink Sheet" Sept. 19, "In Brief"). Genzyme also has production facilities in Cambridge, Mass. and Madistone, England. To reach that level, the company would have to have two very strong final months in 1988.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS014560

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel